NEW YORK (GenomeWeb News) - Beckman Coulter subsidiary Agencourt Bioscience said today that Third Wave Technologies will use its Genfind DNA-isolation system for two human papillomavirus tests that it expects to market in 2009.
Third Wave, now a wholly owned subsidiary of Hologic, submitted its Cervista HPV HR and Cervista HPV 16/18 tests to the US Food and Drug Administration for pre-market approval in April.
The companies said that they are also collaborating on the development of “future applications” for Agencourt’s nucleic acid preparation technology, but did not provide further details of their plans.
Genfind is based on Agencourt’s Solid Phase Reversible Immobilization paramagnetic bead-based nucleic acid purification technology, which eliminates the need for solvents, vacuum filtration, or centrifugation steps, the company said.
Kevin Conroy, president and CEO of Third Wave, said in a statement that Agencourt’s Genfind technology delivers “reliable high recovery of purified DNA” and is easily automated.